Antonia Da Fonseca Ioannou

Antonia Da Fonseca Ioannou

Auto-generated profile, based on publicly available information

Antonia Da Fonseca Ioannou

Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
AIAntonia Da Fonseca Ioannou
Antonia Da Fonseca Ioannou
CTCarolyn Tai
Carolyn Tai
MLMary Anna Labato
Mary Anna Labato
EBEmmanuelle M. Butty
Emmanuelle M. Butty
Background: Outcomes of dogs with acute kidney injury secondary to leptospirosis (AKI-L) treated using renal replacement therapies (RRT) are poorly characterized. Hypothesis/Objectives: Describe survival to discharge, short (≤30 days) and long-term (≥6 months) outcomes of AKI-L dogs receiving RRT and determine if there is a significant difference in maximum blood urea nitrogen (maxBUN), maximum creatinine (maxCr), maximum bilirubin (maxBili) and the number of body systems affected between survivors and non-survivors. Animals: Twenty-two client-owned dogs with AKI-L receiving RRT. Methods: Retrospective medical record review of dogs with AKI-L that received RRT between 2018 and 2021. Results: Sixteen of 22 (73%) dogs survived to discharge. Of the survivors, 13 (81%) were alive >30 days from discharge and 12 (75%) were alive at 6 months from discharge. Factors significantly higher in non-survivors included number of body systems affected (survivors: 1 (19%), 2 (50%), 3 (25%) and 4 (6%) vs non-survivors: 3 (33.3%), and 4 (66.7%); P = .01) and median maxBili (survivors: 1.9 mg/dL; range, 0.1-41.6 vs non-survivors: 21.0 mg/dL; range, 12.3-38.9; P = .02). There was no significant difference in median maxBUN (survivors: 153.0 mg/dL; range, 67-257 vs non-survivors: 185.5 mg/dL; range, 102-218; P = .44) and median maxCr (survivors: 9.8 mg/dL; range, 6.2-15.9 vs non-survivors: 9.8 mg/dL; range, 8.4-13.5; P = .69) between survivors and non-survivors. Conclusions and Clinical Importance: Regardless of azotemia severity, dogs with AKI-L receiving RRT have a good survival rate to discharge. The number of body systems affected and hyperbilirubinemia might be associated with worse outcomes.

2 April 2025 in American Journal of Veterinary Research
Verified
Journal Article
Open access
PDF file
AIAntonia F. Ioannou
Antonia F. Ioannou
FCFrancisco O. Conrado
Francisco O. Conrado
YCYe Chen
Ye Chen
OMOrla Mahony
Orla Mahony
Objective: Comparison of a veterinary glucometer (AlphaTRAK 2 [AT-2]) and 2 human glucometers (FreeStyle Libre 2 [FS-] and FreeStyle Libre 14 [FS-14]) to an automated, wet-chemistry analyzer (reference analyzer). Methods: This was a prospective observational study at Tufts Cummings School of Veterinary Medicine between January 2021 and September 2022 and included 187 client and staff-owned dogs. Following venipuncture, 3 glucometers (FS-14, FS-2, and AT-2) were used to measure blood glucose, and the reference analyzer was used to measure serum glucose. Results: Compared to the reference analyzer, the FS-2 and FS-14 glucometers had a negative bias (mean difference estimates: FS-2, −25.01 mg/dL [95% CI, −60.4 to 10.3]; FS-14, −23.6 mg/dL [95% CI, −60.7 to 13.5]), while the AT-2 glucometer had a positive bias (mean difference estimates: 15.4 mg/dL [95% CI, −41.1 to 72.2]). All glucometers showed significant constant and proportional biases based on Passing-Bablok regression with constant biases of −12.3, −10.05, and −14.25 for the FS-2, FS-14, and AT-2, respectively. Most results were within zone A (FS-2, 50.3%; FS-14, 54.5%; AT-2, 70.1%) and B (FS-2, 49.7%; FS-14, 45.5%; AT-2, 26.2%) of the Clarke error grid. The AT-2 produced values within zone C (1.6%) and zone D (2.1%). Conclusions: All glucometers correlated with the reference analyzer and were clinically useful. As the AT-2 glucometer produced values in the Clarke error grid zones C and D, serum glucose should be measured when results are unexpected or influence the treatment regimen. Clinical Relevance: Despite potential biases, owners can use FS-2 and FS-14 glucometers to verify sensor readings in dogs using continuous glucose monitoring devices.